Retatrutide: What the Phase 1–3 Clinical Trial Series Shows, and What Is Still Unknown
A research overview of retatrutide, the investigational GIP/GLP-1/glucagon triple-receptor agonist: phase 1 and 1b data, phase 2 obesity, diabetes and liver-fat studies, the first published phase 3 results (TRIUMPH-1, TRIUMPH-2, TRANSCEND-T2D-1), open questions, and product-quality findings. PurixLab’s Retatrutide 10mg vial is for laboratory research use only.
Retatrutide: What the Phase 1–3 Clinical Trial Series Shows, and What Is Still Unknown Read More »